Abstract AIMS: Drug-eluting stents (DES) may be associated with an increased risk for stent thrombosis when compared with bare-metal stents. In endothelial cells, rapamycin induces tissue factor (TF) by inhibiting the mammalian target of rapamycin (mTOR). However, the effect of mTOR inhibition on TF activity and thrombus formation in vivo has not yet been studied. Moreover, it is unclear whether second-generation DES substances everolimus and zotarolimus have an effect on endothelial TF expression. METHODS AND RESULTS: In a mouse carotid artery photochemical injury model, rapamycin (182 +/-27.5 microg/L) decreased time to thrombotic occlusion by 40%, increased TF activity, and abrogated p70S6K phosphorylation when compared with controls. In vitro, rapamycin, everolimus, and zotarolimus (each 10(-7) mol/l) enhanced TNF-alpha-induced TF expression by 2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity. Similar to rapamycin, everolimus and zotarolimus abrogated TNF-alpha-induced p70S6K phosphorylation under these conditions. CONCLUSION: Rapamycin increases TF activity and promotes arterial thrombosis in vivo at concentrations relevant in patients undergoing DES implantation; this effect may increase the thrombogenicity of DES. Since everolimus and zotarolimus augment endothelial TF expression and activity in vitro in a similar manner as rapamycin, these findings may also be relevant for second generation DES.
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Methods and Results -In a mouse carotid artery photochemical injury model, rapamycin decreased time to thrombotic occlusion by 40%, increased TF activity, and abrogated p70S6K phosphorylation as compared to controls. In vitro, rapamycin, everolimus, and zotarolimus (each 10 -7 mol/l) enhanced TNF-α induced TF expression by 2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity. Similar to rapamycin, everolimus and zotarolimus abrogated TNF-α-induced p70S6K phosphorylation under these conditions.
Conclusions -Rapamycin increases TF activity and promotes arterial thrombosis in
vivo at concentrations relevant in patients undergoing DES implantation; this effect may increase the thrombogenicity of DES. Since everolimus and zotarolimus augment endothelial TF expression and activity in vitro in a similar manner as rapamycin, these findings may also be relevant for second generation DES.
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INTRODUCTION
Percutaneous coronary intervention (PCI) and stenting of the culprit lesion is the preferred treatment in acute myocardial infarction.(1-3) Drug-eluting stents (DES) are associated with reduced restenosis rates as compared to bare-metal stents (BMS).(4-6) However, stent thrombosis rates are not reduced in DES and may even be higher as compared to BMS, particularly in acute coronary syndromes (ACS). (6) (7) (8) (9) (10) (11) (12) (13) Since it is associated with a high mortality, stent thrombosis remains one of the most dreaded complications of interventional cardiology. Indeed, stent thrombosis is believed to be one possible reason for the lack of a true mortality benefit with DES as compared to BMS. (14, 15) Second-generation DES such as everolimus-and zotarolimus-eluting stents are proposed to display a better safety profile compared to first-generation DES, but long term, large scale clinical data supporting this hypothesis are lacking.
Initiation of coagulation is a pivotal event in the pathogenesis of thrombosis and acute myocardial infarction. Tissue factor (TF) is a key trigger of the coagulation cascade; it activates factor X by binding activated factor VII (FVIIa), which ultimately leads to thrombin formation.(16) Rapamycin, a macrocyclic lacton used on firstgeneration DES, induces TF in human endothelial cells by inhibiting the activity of the mammalian target of rapamycin (mTOR).(17) However, the effect of mTOR inhibition on TF activity and thrombus formation in vivo has not yet been studied. Moreover, whether and to what degree the rapamycin analogues everolimus and zotarolimus exert similar effects on endothelial TF expression is unknown. Thus, the present study was designed to investigate the role of mTOR inhibition on TF induction and arterial thrombosis in vivo and to examine the effect of everolimus and zotarolimus on TF expression human endothelial cells.
MATERIALS AND METHODS
Carotid Artery Thrombosis Model
C57BL/6 mice (6 to 8 weeks old; Charles River Laboratories, Sulzfeld, Germany) weighing an average of 23±2 g were treated with rapamycin (2 mg/kg body weight) or with vehicle by intraperitoneal injection. After 1 hour, mice were anesthetized with intraperitoneal injection of 2 mg of sodium pentobarbital (Butler, Columbus, Ohio) as described previously.(18, 19) Rose Bengal (Fisher Scientific, Fair Lawn, NJ) was diluted to 10 mg/mL in PBS and then injected into the tail vein in a volume of 0.12 mL at a final concentration of 50 mg/kg with a 27-gauge Precision Glide needle with a 1-mL latex free syringe (Becton Dickinson, Franklin Lakes, NJ).
Once anesthetized, mice were secured in a supine position, placed under a dissecting microscope (Olympus C-4040 Zoom; spatial resolution 4.1 megapixels, Olympus Schweiz, AG, Switzerland), and the right common carotid artery was 
Tissue factor activity in vitro and in vivo
TF cell surface and total tissue activity were analyzed in HAEC and mouse carotid artery homogenates, respectively, with a colorimetric assay (American Diagnostica) as described. (19, 21) HAEC were grown in 12-well plates; after stimulation, cells were washed twice with phosphate-buffered saline (PBS) followed by incubation with human factor VIIa (FVIIa) and factor X (FX) at 37°C, resulting in the formation of TF/FVIIa complex at the cell surface. Right carotid arteries were homogenized in 50μL of lysis buffer (50 mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton X-100, pH 7.4) 1 hour after intraperitoneal application of rapamycin (2 mg/kg body weight) or vehicle and left to stand on ice for 30 minutes. In either case, the TF/FVIIa complex converted human FX to factor Xa, which was measured by its ability to cleave a chromogenic substrate. A standard curve with lipidated human TF was performed to ensure that measurements were taken in the linear range of detection (data not shown).
Cell culture
HAEC were cultured as described.(21) Cells were grown to confluence in 3.5 cm dishes and rendered quiescent for 24 hours before stimulation with TNF-α (Sigma, Munich, Germany). Rapamycin, everolimus (both from Sigma), and zotarolimus (a kind gift from Abbott Vascular, Santa Clara, CA) were added 60 minutes prior to stimulation.
Western blot analysis
Protein expression was determined by Western blot analysis.(17) Cells were lysed in 50 mM TRIS buffer and 30-40 µg samples were loaded and separated by 10% SDS-PAGE. Proteins were transferred to a PVDF membrane (Millipore, Billerica, MA) by semidry transfer. The antibody to human TF (American Diagnostica, Pfungstadt, Germany) was used at 1:1000 dilution; antibodies against the phosphorylated Thr-389-residue of p70S6 kinase (S6K) and against total S6K (both from Cell Signaling) were used at 1:1'000 and 1:2'000 dilution, respectively. Blots were normalized to GAPDH expression (1:20'000 dilution, Sigma).
1 hour after intraperitoneal application of rapamycin (2 mg/kg body weight) or vehicle (2.5% DMSO in phosphate buffered saline (PBS)), aortas of mice were homogenized in 50 μL of lysis buffer (50 mmol Tris-HCl, 100 mmol NaCl, 0.1% Triton X-100, pH 7.4) and left to stand on ice for 30 minutes. 100 μg samples were loaded and separated by 10% SDS-PAGE; proteins were transferred to a PVDF membrane and probed with an antibody to phosphorylated p70S6K (1:1000 dilution) or total p70S6K (1:2000 dilution).
Statistics
Data are presented as mean ± standard error of the mean (SEM). Unpaired Student t test was applied to compare 2 groups; ANOVA with Bonferroni's correction was used for ≥ 3 groups. A p value <0.05 was considered significant. Phosphorylation of p70S6K, a downstream target of mTOR, is frequently used to assess mTOR inhibition by rapamycin, (17, 23, 24 ) and abrogation of p70S6K phosphorylation leads to an increase in TF expression and activity.(17) While a prominent phosphorylation of p70S6K was observed in aortas of mice treated with vehicle, it was abrogated in rapamycin-treated animals ( Fig. 1C; p<0 .01).
RESULTS
Rapamycin inhibits mTOR, increases
There was no change in activated partial thromboplastin time (aPTT; 25.5 ± 0.5 sec. vs. 24.4 ± 0.8 sec., p=n.s.) or prothrombin time (PT; 11.1 ± 0.1 sec. vs. 11.4 ± 0.2 sec., p=n.s.) in rapamycin-treated versus control mice, respectively (Table 1) .
Rapamycin enhances TF expression in human endothelial cells
Stimulation of HAEC with TNF-α (5 ng/ml) induced TF protein expression ( mol/l) resulted in a concentration-dependent enhancement of TF expression with a maximal increase of 2.2-fold as compared to stimulation with TNF-α alone and 75-fold as compared to the unstimulated control (Fig 2A; p<0 .02 for rapamycin 10 -7 mol/l vs. TNF-α alone). Rapamycin (10 -7 mol/l) abrogated p70S6K phosphorylation (Fig. 2B ).
Everolimus and zotarolimus enhance TF expression in human endothelial cells
Like rapamycin, everolimus (10 mol/l), the maximal increase in TF induction was 2.2-, 1.7-, and 2.4-fold for rapamycin, everolimus, and zotarolimus, respectively, as compared to TNF-α ( Fig. 3A; p<0.005 for everolimus vs. TNF-α alone and p<0.001 for zotarolimus vs. TNF-α alone). TF induction by zotarolimus+TNF-α was 1.4-fold higher as compared to everolimus+TNF-α (p<0.05).
Rapamycin increased TNF-α induced TF surface activity by 1.5-fold; similarly, everolimus and zotarolimus augmented TNF-α induced TF surface activity by 1.4-fold and 1.5-fold, respectively ( Fig. 3B ; p<0.01 for everolimus or zotarolimus vs. TNF-α alone). Similar to rapamycin (Fig 2B), everolimus (Fig. 3C , upper panel) and zotarolimus (Fig. 3C, lower panel) abrogated TNF-α induced p70S6K phosphorylation.
DISCUSSION
Rapamycin was previously shown to induce TF in vitro; yet, the physiological significance of this effect has not been assessed. (17) The findings of the present study suggest that this effect is also relevant in vivo, since inhibition of mTOR by rapamycin increases TF activity and promotes arterial thrombosis in the mouse carotid artery exposed to laser injury. Moreover, everolimus and zotarolimus inhibit mTOR and enhance TF expression and activity in human endothelial cells similar to rapamycin, indicating that these findings may be relevant both for first-and second generation DES. While the current study compares the in vitro TF induction of rapamycin, everolimus, and zotarolimus it does not compare TF activity and thrombus formation in vivo amongst the three drugs; in order to do so correctly and adequately, measurement of in vivo plasma levels over time of all three drugs as well as appropriate adjustment of the applied doses of the drugs would be required, which seems beyond the scope of the current study. Instead, we demonstrate for the first time in vivo (as a proof-of-principle) that rapamycin inhibits arterial mTOR activity, increases arterial TF activity and promotes thrombus formation without affecting systemic coagulation parameters. Given the similar effect of everolimus and zotarolimus on TF expression as well as on p70S6K phosphorylation in vitro, an increase in TF activity and promotion of thrombus formation in vivo is nevertheless likely to occur with these two drugs as well.
In summary, this study reveals that inhibition of mTOR increases TF activity and promotes arterial thrombosis in vivo, which may favor the development of thrombosis in DES. As everolimus and zotarolimus equally increase TF expression and activity in vitro, these findings may be relevant for both first-and second generation DES. aPTT and PT were unchanged 1 hour after treatment of mice with rapamycin (2 mg/kg body weight) as compared to vehicle treated mice (p=n.s.). 
